Psoriasis is a systemic chronic skin disorder characterized by excessive keratinocytes proliferation that results into thickened scaly plaques, itching and inflammatory changes in the epidermis and dermis. It is transmitted genetically but can be provoked by environmental factors.
It is found in approximately 2% of the population that primarily affects the skin and joints.
It is associated with other inflammatory disorders and autoimmune diseases (eg psoriatic arthritis, inflammatory bowel disease, coronary artery disease).
Generally, it begins as red scaling papules that coalesce to form round-to-oval plaques. The rashes are often pruritic and may be painful.
Interleukin 17A (IL-17A) inhibitors show better efficacy than ustekinumab in achieving clearance in adults with moderate-to-severe plaque psoriasis, a recent study has shown. Additionally, IL-17A inhibitors are generally more effective than etanercept, adalimumab and apremilast.
New drug applications approved by US FDA as of 16 - 31 March 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvalsmay have occurred since the original approval date.
The approved psoriasis therapy ustekinumab also reduces aortic vascular inflammation, along with improved psoriasis severity, compared with placebo in patients with moderate-to-severe psoriasis, according to the VIP-U* study presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, US.
In patients with psoriasis, ocular surface involvement implies the need for periodic ophthalmological examinations to diagnose the condition and allow proper treatment, which may help improve the patients’ quality of life, suggests a recent study.
Infliximab and adalimumab are both effective for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease, while other biologics have shown efficacy for some, but not all, of these indications, according to the results of a systematic review.
Adjunct Associate Professor Chong Wei Sheng, Head of the Psoriasis Unit at the National Skin Centre, Singapore, speaks to Roshini Claire Anthony on the vital role played by primary care physicians (GPs) in tackling psoriasis.
Individuals with obesity and high abdominal fat mass appear to have a twofold increased risk of developing psoriasis, as shown in a study. Long-term weight gain of ≥10 kg is also associated with a substantially increased risk.
Researchers have recently developed and validated a prediction rule to identify patients with moderate-to-severe psoriasis who are not likely to respond adequately to methotrexate, reports a study. The rule indicates that 4 weeks of methotrexate may be enough to predict long-term response with limited safety risk.